FDA approves expanded use of Adacel vaccineAdacel is now the first and only Tdap vaccine in the United States approved for a repeat dose in people between the ages of 10-to-64 years old, administered eight or more years after the first vaccination. Acorda Therapeutics' Inbrija gets approvalAcorda Therapeutics' Inbrija helps patients who may experience OFF episodes as Parkinson’s progresses. Amgen's Nplate pediatric indication gets FDA approval Amgen has received the Food and Drug Administration's approval for Nplate for pediatric patients with immune thrombocytopenia. Amgen cuts prices for Repatha devices Amgen’s Repatha device options, including its prefilled syringe, are being offered at a 60% reduced price of $5,850 per year. Braeburn's Brixadi gets tentative approval Braeburn's Brixadi offers treatment for patients with moderate-to-severe opioid use disorder. Pliaglis’ ‘Not for Home Use’ label restriction gets green lighted Crescita's Pliaglis received approval from the Food and Drug Administration for removal of the "Not for Home Use" label restriction. Hikma, Sciecure Pharma ink deal for niche injectable anti-viral medicines Hikma expects its deal with Sciecure will expand its pipeline of niche products. FDA approves new Sprycel indication The Food and Drug Administration has given Bristol-Myers Squibb approval for a new pediatric indication for Sprycel. Sanofi, Merck get Vaxelis approval Sanofi and Merck received the FDA's approval for a new vaccine that will not have a commerical supply available in the United States prior to 2020. Lupin, AbbVie partner to develop cancer drugs Lupin and AbbVie have formed a partnership to develop Lupin's MALT1 inhibitors. First Previous 42 43 44 45 46 Next Last
